Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer

Sensitizing mutations in the epidermal growth factor receptor (EGFR) predict response to EGFR tyrosine kinase inhibitors (TKIs) and both first- and second-generation TKIs are available as first-line treatment options in patients with advanced EGFR-mutant non-small cell lung cancer. Eventual resistan...

Descripción completa

Detalles Bibliográficos
Autores principales: Barnes, Tristan A., O’Kane, Grainne M., Vincent, Mark David, Leighl, Natasha B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5449484/
https://www.ncbi.nlm.nih.gov/pubmed/28620581
http://dx.doi.org/10.3389/fonc.2017.00113

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5449484/
https://www.ncbi.nlm.nih.gov/pubmed/28620581
http://dx.doi.org/10.3389/fonc.2017.00113

Ejemplares similares